View Future Growthgenedrive 과거 순이익 실적과거 기준 점검 0/6genedrive은 연평균 1%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 연평균 4.7%의 비율로 증가했습니다. 매출은 연평균 19.3%의 비율로 증가했습니다.핵심 정보1.04%순이익 성장률47.41%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률19.27%자기자본이익률n/a순이익률-455.11%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트genedrive plc to Report Fiscal Year 2025 Results on Dec 05, 2025Dec 03genedrive plc to Report Fiscal Year 2024 Results on Nov 29, 2024Nov 22genedrive plc to Report First Half, 2024 Results on Mar 28, 2024Mar 16Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022) Dec 01genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023Nov 17Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021) Nov 22모든 업데이트 보기Recent updatesGenedrive plc Announces Nhs England Commercial Strategy for Rapid Mt-Rnr1 TestingApr 23genedrive plc has completed a Follow-on Equity Offering in the amount of £0.909643 million.Mar 09genedrive plc has completed a Follow-on Equity Offering in the amount of £0.5 million.Feb 14+ 2 more updatesgenedrive plc, Annual General Meeting, Dec 31, 2025Dec 09genedrive plc to Report Fiscal Year 2025 Results on Dec 05, 2025Dec 03genedrive plc Announces Pilot Programme Study Results Underpinning Nhs Implementation Guide for Cyp2c19 Genotype Testing Presented At the Uk Stroke ForumDec 02Genedrive plc Announces Nhs Implementation Guide Published for Cyp2c19 Genotype TestingNov 27genedrive plc Announces Scotland National Roll-Out of Genedrive MT-RNR1 ID KitNov 26genedrive plc has completed a Follow-on Equity Offering in the amount of £3.1975 million.Sep 25+ 1 more updategenedrive plc has filed a Follow-on Equity Offering in the amount of £0.3 million.Sep 24genedrive plc Announces the Genedrive MT-RNR1 ID Kit Is Being Introduces by NHS Greater Glasgow and ClydeAug 21Genedrive plc Provides Earnings Guidance for the Year Ending June 30, 2025Aug 13genedrive CYP2C19 ID Kit Receives CE-Certification Under the European in Vitro Diagnostics RegulationMay 30genedrive plc Announces CYP2C19 ID Kit CE-IVD Certification UpdateMay 05genedrive plc has completed a Follow-on Equity Offering in the amount of £0.226309 million.Apr 01genedrive plc has filed a Follow-on Equity Offering.Mar 28genedrive plc has filed a Follow-on Equity Offering in the amount of £1 million.Mar 27genedrive plc, Annual General Meeting, Dec 30, 2024Dec 07genedrive plc to Report Fiscal Year 2024 Results on Nov 29, 2024Nov 22genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life SciencesNov 21New minor risk - Financial data availability Oct 14Genedrive plc Announces CEO ChangesAug 06Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug AdministrationJul 15genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.May 31genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.May 11New major risk - Shareholder dilution Apr 06genedrive plc to Report First Half, 2024 Results on Mar 28, 2024Mar 16New major risk - Market cap size Feb 07genedrive plc, Annual General Meeting, Dec 29, 2023Dec 07Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022) Dec 01New major risk - Market cap size Nov 21genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023Nov 17New minor risk - Financial data availability Oct 18genedrive plc Announces Chief Executive Officer ChangesSep 12Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 SystemSep 06genedrive plc, Annual General Meeting, Dec 29, 2022Dec 06Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021) Nov 22genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022Nov 14genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product RangeOct 06Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel TreatmentAug 22NICE to Evaluate the Genedrive MT-RNR1 TestJun 16High number of new directors May 31Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory AgencyMay 31High number of new directors Apr 27Now 24% undervalued Apr 06First half 2022 earnings released Mar 30Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 TestMar 30genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial OfficerMar 03Genedrive plc Provides Update on Point of Care Covid TestFeb 24genedrive plc to Report First Half, 2022 Results on Mar 29, 2022Feb 04genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kitDec 23Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020) Nov 10Insufficient new directors Sep 02Genedrive COVID-19 Point of Care device updateJul 02First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020) Mar 28genedrive plc Enters Distribution Agreement with Mountain Horse SolutionsMar 09genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss AssayMar 04New 90-day high: €1.05 Feb 07genedrive plc Enters into Distribution Agreement with Beckman Coulter Life SciencesJan 29genedrive plc to Report First Half, 2021 Results on Mar 25, 2021Jan 19New 90-day low: €0.32 Jan 14genedrive plc, Annual General Meeting, Dec 30, 2020Jan 01New 90-day low: €0.37 Dec 12Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation StudyDec 04Revenue misses expectations Nov 30Full year 2020 earnings released: UK£0.55 loss per share Nov 30Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India StudyNov 20Full year 2020 earnings released: UK£0.55 loss per share Nov 19Revenue misses expectations Nov 19New 90-day low: €0.71 Nov 09genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020Oct 29genedrive plc Announces South African ApprovalOct 04genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNASep 26New 90-day high: €1.48 Sep 22매출 및 비용 세부 내역genedrive가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:D6M 매출, 비용 및 순이익 (GBP Millions)날짜매출순이익일반관리비연구개발비31 Dec 251-52030 Sep 251-52030 Jun 251-52031 Mar 251-62031 Dec 241-72030 Sep 241-72030 Jun 241-72031 Mar 240-62031 Dec 230-51030 Sep 230-51030 Jun 230-51031 Mar 230-51031 Dec 220-52030 Sep 220-52030 Jun 220-52031 Mar 220-42031 Dec 210-42030 Sep 211-22030 Jun 211-12031 Mar 211-82031 Dec 201-152030 Sep 201-172030 Jun 201-192031 Mar 201-122031 Dec 192-52030 Sep 192-42030 Jun 192-42031 Mar 192-52031 Dec 182-72030 Sep 182-72030 Jun 182-72031 Dec 171-63030 Sep 172-63030 Jun 173-73031 Mar 176-62031 Dec 166-52030 Sep 166-62030 Jun 165-62031 Mar 165-52031 Dec 154-52030 Sep 154-42030 Jun 155-320양질의 수익: D6M 은(는) 현재 수익성이 없습니다.이익 마진 증가: D6M는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: D6M는 수익성이 없지만 지난 5년 동안 연평균 1%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 D6M의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: D6M은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(13.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: D6M의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/02 16:18종가2026/04/30 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스genedrive plc는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mark BrewerCavendishJohn SavinEdison Investment ResearchNigel Bligh HawkinsHardman & Co.2명의 분석가 더 보기
genedrive plc has completed a Follow-on Equity Offering in the amount of £0.5 million.Feb 14+ 2 more updates
genedrive plc Announces Pilot Programme Study Results Underpinning Nhs Implementation Guide for Cyp2c19 Genotype Testing Presented At the Uk Stroke ForumDec 02
genedrive plc has completed a Follow-on Equity Offering in the amount of £3.1975 million.Sep 25+ 1 more update
genedrive plc Announces the Genedrive MT-RNR1 ID Kit Is Being Introduces by NHS Greater Glasgow and ClydeAug 21
genedrive CYP2C19 ID Kit Receives CE-Certification Under the European in Vitro Diagnostics RegulationMay 30
genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life SciencesNov 21
Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug AdministrationJul 15
Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel TreatmentAug 22
Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory AgencyMay 31
Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation StudyDec 04
genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNASep 26